



Published in final edited form as:

Cell Immunol. 2023 May ; 387: 104707. doi:10.1016/j.cellimm.2023.104707.

Analysis of the different subpeptidomes presented by the HLA class I molecules of the B7 supertype

Adrián Tirado-Herranz^{1,2,†}, Pablo Guasp^{3,4,†}, Alba Pastor-Moreno^{1,2}, María Area-Navarro^{1,2}, Iñaki Alvarez^{1,2,*}

¹Immunology Unit, Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona, 08193 Bellaterra, Spain

²Institute of Biotechnology and Biomedicine, Autonomous University of Barcelona, 08193 Bellaterra, Spain

³Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

⁴Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Abstract

MHC-I molecules of the HLA-B7 supertype preferentially bind peptides with proline at position 2. HLA-B*51:01 and B*51:08 present two predominant subpeptidomes, one with Pro2 and hydrophobic residues at P1, and another with Ala2 and Asp enriched at position 1. Here, we present a meta-analysis of the peptidomes presented by molecules of the B7 supertype to investigate the presence of subpeptidomes across different allotypes. Several allotypes presented subpeptidomes differing in the presence of Pro or another residue at P2. The Ala2 subpeptidomes preferred Asp1 except in HLA-B*54:01, where ligands with Ala2 contained Glu1. Sequence alignment and the analysis of crystal structures allowed us to propose positions 45 and 67 of the MHC heavy chain as relevant for the presence of subpeptidomes. Deciphering the principles behind the presence of subpeptidomes could improve our understanding of antigen presentation in other MHC-I molecules.

Keywords

HLA; antigen presentation; immunopeptidome; B7 supertype; peptide

* **Correspondence:** Iñaki Álvarez PhD. Phone: 34-93-581 3237. Fax: 34-93-581 2011. Inaki.Alvarez@uab.cat, Postal address: Cellular Immunology laboratory, Institut de Biotecnologia i Biomedicina, Campus de Bellaterra, 08193, Bellaterra, Barcelona, Spain.

[†]These authors have contributed equally to this work.

Author Contributions

AT and PG: conceptualization, methodology, data curation. AP and MA; methodology, data curation. IA: conceptualization, writing original draft preparation, supervision and validation.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

1 Introduction

Human leukocytes antigens class I molecules (HLA-I) bind peptides derived from cytosolic or nuclear proteins and present them to cytotoxic T lymphocytes (CTL), which are able to discriminate between “self” and “non-self” peptides and subsequently kill infected or transformed cells. HLA-I are heterodimers composed of a heavy and variable α chain encoded in the major histocompatibility complex (MHC) region and a light and constant chain, beta-2-microglobulin (β_2m), encoded outside the MHC. The distal extracellular α_1 and α_2 domains of the heavy chain form the peptide binding site, composed by two α helices and a β sheet of 8 anti-parallel β strands, forming six different pockets that accommodate the side chains of some residues of the peptide [1]. In HLA-I, the most restrictive pockets are those that bind the side chains of the second and last peptide positions (P2 and P Ω , respectively) [2]. Three *loci* encode the heavy chain of the classical HLA-I molecules: *HLA-A*, *HLA-B* and *HLA-C*. *HLA* genes are the most polymorphic genes in the genome, and most of their polymorphisms are located in the peptide binding site, making different HLA molecules bind different peptidomes with specific anchor motifs [2]. The interaction of HLA-I with specific residues of the peptide restricts the number of potential ligands. Thus, the correct identification of the anchor motifs from the different HLA-I allotypes is crucial to properly predict which peptides from a given protein have the potential to bind to each HLA molecule and be presented to CTLs.

HLA-B molecules have been grouped in 6 different supertypes based on the anchor motifs of their peptide ligands, called B7, B8, B27, B44, B58 and B62 supertypes [3-7]. HLA-I molecules belonging to the same supertype bind partially overlapping peptidomes. The B7 supertype is composed of HLA-B molecules that bind Pro at the P2 peptide position and aromatic, aliphatic and hydrophobic residues at their P Ω [3].

HLA-B*51:01 and -B*51:08, two members of the B7 supertype, bind peptides with Pro2 or Ala2 and hydrophobic residues at P Ω [8-11]. Previous work reported that the peptide repertoires bound to these allotypes are composed by two different subpeptidomes: one with Pro2 and a preference for hydrophobic residues at P1, and one containing Ala2 with preference for Asp1 [12], and subsequently confirmed [13]. More recently, it was described the presence of subpeptidomes in other HLA-I peptide pools [13, 14], showing that it is not unique to the -B*51 subtypes.

The presence or absence of subpeptidomes and the different features that can show these subpeptidomes among close related HLA-I molecules may explain the presentation or not of putative relevant T cell epitopes from pathogens or self-antigens. In addition, the knowledge of the structural features explaining the presence of subpeptidomes may be useful to predict which allotypes are able to bind specific peptides.

Here, we present a meta-analysis of the peptidomes of 13 HLA-I molecules belonging to the -B7 supertype: we analyzed the presence or absence of subpeptidomes and the effect of the amino acid variation at the anchor position 2 on the residue at position 1. The presence of subpeptidomes varied among the HLA-B7 allotypes. Sequence alignment of the HLA-I molecules strongly suggests that residues Thr45 and Phe67 are important for the

presence of subpeptidomes in the B7 supertype molecules. Positions 45 and 67 are part of the Pocket B [15] and have been described to alter peptide presentation [16]. Finally, the analysis of multiple crystal structures of -B*07:01, -B*35:01 and -B*51:01 showed that the orientation of residue Asn63 varied depending on the presence of Glu45-Tyr67 (in -B*07:01) or Thr45-Phe67 (in -B*35:01 and -B*51:01).

2 Materials and methods

HLA-B peptidomes

Peptidomes from Immuno Epitope Database and Analysis Resource (IEDB) were extracted at 02-15-2022. Duplicated peptides in any HLA-B peptidome were eliminated and considered only once. Peptides with or without post-translational modifications were treated as unique non-modified peptides. Only peptidomes from HLA-B molecules with more than 500 peptides were included in this study.

2.1 Identification of the HLA-I anchor motifs

To determine the HLA-I anchor motifs, peptidomes were analyzed with the Peptide Repertoire-Based Anchor Motif (PRBAM) program [17]. In order to simplify the output, only nonamers were analyzed to define the anchor motifs of these allotypes.

2.2 MHC binding affinities of HLA-I ligands.

The theoretical affinity of the peptides for HLA-I molecules was calculated using the NetMHC4.0 1.1 Server (<http://www.cbs.dtu.dk/services/NetMHC/>) [18, 19].

2.3 Statistical analysis.

Differences in residue frequencies were analyzed by chi-square test with Bonferroni correction as previously described [12].

Differences in MHC binding affinities were analyzed by the Mann-Whitney U test. Different P values were considered.

2.4 Analysis of crystal structures

Crystal structures of different HLA molecules were previously reported and deposited on the Protein Data Bank (PDB, [rcsb.org](https://www.rcsb.org/)) [20]. To perform the analysis, three crystals structures of HLA-B*51:01: 1E27, 1E28, 4MJI [21, 22], twelve of HLA-B*07:02: 3VCL [23], 5EO, 5EO1 [24], 5WMN, 5WMO, 5WMP [25], 6AT5 [26], 6UJ7, 6UJ8 [27], 7LG0, 7LGD, 7LGT [28] and eighteen of HLA-B*35:01: 1A1N [29], 1A9B, 1A9E [30], 1XH3 [31], 1ZSD [32], 2AXG [33], 2CIK [34], 2FYY, 2FZ3 [35], 2H6P [36], 3LKN, 3LKO, 3LKP, 3LKQ, 3LKR [37], 4PR5, 4PRA, 4PRN [38] were chosen. Sequences were aligned and analyzed using the PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.

3 Results

3.1 Features of the B7 supertype peptidomes

We obtained the peptide repertoires of different HLA-B molecules belonging to the B7 supertype from IEDB [39]. Peptidomes with more than 500 peptides ranging from 8 to 13 residues long were considered. Following this criterium, we selected 13 peptidomes, derived from HLA-B*07:02, -B*07:04, -B*35:01, -B*35:03, -B*35:07, -B*42:01, -B*51:01, -B*51:08, -B*53:01, -B*54:01, -B*55:01, -B*55:02 and -B*56:01. Figure 1 shows the sequence alignment of these proteins. The number of reported peptides from each molecule ranged from 624 to 12033 peptides (Table 1). As expected, nonamers comprised the majority of each peptidome (from 49.5% to 77.9%), with the percentage of octamers and peptides 10-13 residues long varying among different allotypes. HLA-B*51:01 and -B*51:08 contained the highest proportion of octamers (27.4% and 13.6%, respectively) and the lowest number of peptides of 10 or more residues. In contrast, HLA-B*07:02, -B*07:04, -B*55:02 and -B*56:01 bound more than 20% of 10-mer and more than 10% of 11-mer peptides. The average number of residues in the analyzed peptidomes was similar (ranging from 9.3 to 9.7), except for the two B*51 alleles, with an average number of 9.0 residues.

The B7 supertype is characterized by the presence of Pro at P2 and aromatic, aliphatic and hydrophobic residues at PΩ [3]. We analyzed the degree of overlap between the peptidomes of the different members of the B7 supertype. The 13 peptide pools were composed of a total of 27039 peptides, of which 6134 (22.7%) were shared by at least two allotypes and 2445 (9.0%) by at least three HLA-I molecules. The degree of overlap was analyzed by pairs of HLA-B molecules (Table 2). In general, peptidomes from different subtypes of the same allele group (HLA-B*07:02 with -B*07:04; -B*35:01 with -B*35:03 and -B*35:07; -B*51:01 with -B*51:08; and -B*55:01 with -B*55:02) shared a higher number of peptides than with other molecules. Nevertheless, in this dataset, the highest overlap was found between HLA-B*55:02 and -B*56:01, sharing 1207 peptides (77.9% and 57.1% of the -B*55:02 and -B*56:01 peptide repertoires, respectively) (Table 2).

3.2 Anchor motifs of the B7 supertype HLA molecules

All 13 molecules bind preferentially peptides with Pro2, while peptides with Ala2 are tolerated to different degree, ranging from 2.6% of the peptidome in B*55:02 and B*56:01 to 54.3% in B*51:08 (Table 3). To further characterize the anchor motifs of these molecules, their peptidomes were analyzed with the PRBAM software. This software identifies the anchor motifs of HLA-I and HLA-DR molecules based on the amino acid abundance at each position. The program returns a deviation from the mean in the proteome (DMP) value for each amino acid in each peptide position. The resulting anchor motifs for nonamers are shown in Supplementary Figure 1. Seven allotypes presented peptidomes with favored Ala2 (the detected abundance of Ala at P2 is higher than its abundance in the human proteome): HLA-B*35:01, -B*35:03, -B*35:07, -B*51:01, -B*51:08, -B*53:01 and -B*54:01 (Supplementary Figure 1).

3.3 HLA-B*54:01 presents, as B*51:01 and B*51:08, two subpeptidomes with favored acid residues in P1, but with Glu1 preferred to Asp1 in the subpeptidome containing Ala2

The peptide repertoire of HLA-B*51:01 was previously described based on the identification of 1620 eluted peptides, and two different subpeptidomes were identified based on the presence of Pro or Ala at P2. Peptides with Pro2 contained mostly aliphatic and aromatic residues at P1, while peptides with Ala2 showed preferentially Asp at P1 [12]. We expanded the analysis with 5157 ligands from the IEDB obtaining similar results, with peptides with Pro2 presenting aliphatic or aromatic residues at P1 and peptides with Ala1 containing mainly Asp1 (Figure 2).

The HLA-B*51:08 peptidome, containing 624 unique peptides, was analyzed previously [40]. As shown in Figure 2, the HLA-B*51:08 peptide repertoire is also composed by two subpeptidomes with the same features than those of HLA-B*51:01.

The IEDB peptidome of HLA-B*54:01 consisted of 1441 peptides, from which 1038 (72.0%) contained Pro2, 145 (10.1%) Ala2 and 258 (17.9%) other amino acids at P2. As in HLA-B*51:01 and -B*51:08, the Ala2 subpeptidome from HLA-B*54:01 showed an increase in acidic residues at P1. Interestingly, peptides contained more Glu1 than Asp1. Peptides with Pro2 presented aliphatic or aromatic residues in P1.

Thus, the existence of two subpeptidomes, one with Pro2 associated to a prevalence of hydrophobic residues at P1 and a second one with Ala2 and acidic residues at P1, is present in at least other molecule of the B7 supertype different to the B*51 subtypes.

3.4 HLA-B35 subtypes and HLA-B*53:01 show two subpeptidomes with polar and acidic residues favored at P1 in the subpeptidome containing Ala2

The HLA-B*35:01, -B*35:03, -B*35:07 and -B*53:01 peptidomes also presented, in addition to Pro2, Ala increased at P2 (Table 3 and Supplementary Figure 1). The analysis of these peptidomes indicated that the subpeptidomes containing Pro2 presented a preference for aliphatic or aromatic residues at P1, while the subpeptidome with Ala2 preferred for polar and acidic residues. In this case, polar residues (Ser, Thr, Asn and Gln) were preferred at P1 to Asp and Glu (Figure 3). In conclusion, HLA-B*35:01, -B*35:03, -B*35:07 and -B*53:01 present two subpeptidomes: one with Pro2 and preference for hydrophobic residues at P1, and another one presenting Ala2 and polar and acidic residues favored at P1.

3.5 Other HLA-B molecules of the B7 supertype do not present apparent subpeptidomes

The peptide repertoires of the other HLA-B molecules of the B7 supertype obtained from the IEDB (HLA-B*07:02, -B*07:04, -B*42:01, -B*55:01, -B*55:02 and -B*56:01) only had Pro favored at P2. Although peptides with Ala2 were not favored in these peptidomes, some ligands of these molecules contained Ala at P2 (with an abundance ranging from 2.6% to 3.9% of the total peptides). We analyzed the residue usage at P1 of these peptides and compared it to that from Pro2 peptides. As shown in Figure 4, we were not able to detect significant differences at P1, contrary to what was observed in other members of the B7 supertype, although Pro and Gly were increased in the peptides containing Ala2 and Ser and Arg tended to be increased in the peptides with Pro2.

3.6 Peptidomes containing different amino acids than Pro or Ala at P2 show similar features to the Ala2 subpeptidome

A considerable number of peptides contained different residues than Pro or Ala at P2 (Table 3). To evaluate whether these peptides are similar to the Pro2 or Ala2 subpeptidomes, or instead form a third subpeptidome on their own, we compared this peptide pool with those containing Pro2 or Ala2. In general, this peptide pool was similar to those with the subpeptidome of Ala2 in reference to the P1 composition (Supplementary Figure 2 and Supplementary Figure 3).

3.7 The presence of Thr45 and Phe67 instead of Glu45 and Tyr67 is associated with the presence of subpeptidomes in the B7 supertype molecules

The α chain sequence alignment of the members of the B7 supertype indicated that molecules that do not present subpeptidomes contain Glu45, while the alleles that present subpeptidomes contain Thr45, except for HLA-B*54:01 which has Gly45 (Table 4). In addition, Phe67 is present in the alleles with subpeptidomes, except for HLA-B*54:01 which, like the allotypes without apparent subpeptidomes, contains Tyr67.

The analysis of multiple crystal structures of HLA-B*07:02 showed that Glu45 directly interacts with Tyr67 and Asn63 (a non-polymorphic residue present in all the allotypes analyzed) (Figure 5A and Supplementary figure 4). This interaction does not exist when Thr and Phe are present at positions 45 and 67, respectively, as is the case of -B*35:01 and -B*51:01 (Figure 5B and 5C and Supplementary figure 4). The interaction of Glu45 with Asn63 changes the orientation of the latter compared to the orientation of this residue in the allotypes that contain different subpeptidomes (Figure 5 and Supplementary figure 4).

3.8 Residue 116 defines different residue preferences at the peptide C-terminal position

We can identify three main groups based on the peptide C-terminal residue usage: 1) HLA-B*35:01, -B*35:07 and -B*53:01 present mainly aromatic residues at P Ω ; 2) HLA-B*54:01, -B*55:01, -B*55:02 and -B*56:01 bind peptides with Ala or Val at P Ω ; 3) the rest of the analyzed allotypes bind peptides with Leu or Met at P Ω (HLA-B*07:02, -B*07:04, -B*35:03 and -B*42:01) or Leu or Val (HLA-B*51:01 and -B*51:08) at P Ω (Supplementary Figure 1). The analysis of the HLA residues that interact with the F pocket revealed that the presence of different residues at position 116 is associated with the preference for specific amino acids at P Ω . Thus, the allotypes that bind peptides with aromatic residues at the C-terminus have Ser116, the ones that bind Ala or Val contain Leu116, and the molecules binding peptides with Leu, Met or Val at C-terminus with as the most abundant amino acids have Tyr116, except for HLA-B*35:03 that has Phe116 (both aromatic residues) (Table 4).

3.9 Theoretical binding affinity of ligands to HLA molecules of the B7 supertype

The theoretical binding affinity of the peptides bound to different members of the B7 supertype was evaluated with NetMHC 4.1, a powerful tool that calculates the affinity of peptides to HLA-I molecules. We analyzed all the molecules included in this analysis that were available to study in NetMHC4.1. These molecules were: HLA-B*07:02, -B*35:01, -B*35:03, -B*51:01, -B*53:01 and -B*54:01. The predicted affinity of the peptides with Pro2 to their corresponding HLA-B molecule was consistently higher than those with Ala2

(Figure 6). Interestingly, in the case of -B*07:02, the subpeptidome containing Ala2 showed a lower theoretical affinity than the total immunopeptidome. In the other HLA-I molecules, which present preferences by acidic or polar residues in P1, the theoretical affinity was similar or higher than that of the total peptidome (Figure 6).

4 Discussion

It has been described that some HLA alleles show multiple specificities for their ligands [13]. In this study, we analyzed the peptidomes presented by 13 allotypes belonging to the HLA-B7 supertype. We found that, although all the B7 molecules can bind Pro and Ala (in addition to other less abundant residues) at P2, several members of the B7 supertype, but not all, present two subpeptidomes in which these amino acids are favored at P2, a feature previously described in HLA-B*51:01 and -B*51:08 [12, 40]. We analyzed the effect of the presence of these amino acids at P2 on the residues favored at P1 and analyzed the structural features involved in this effect. Although the presence of subpeptidomes have been previously reported in different HLA-I molecules [13, 14], to our knowledge, this is the first study that systematically characterizes the presence of subpeptidomes across different members of the B7 supertype and provides a structural explanation for the existence of such subpeptidomes.

The peptidomes presented by the analyzed members of the B7 supertype showed different degrees of overlap, being in general higher among the subtypes of the same allele group. However, the most similar peptidomes were those from HLA-B*55:02 and -B*56:01. Both alleles contain Val152, a position described to affect peptide selection at the internal positions [40, 41], which could explain the lower overlap with the peptidome presented by HLA-B*55:01, which carries Glu152. HLA-B*55 and -B*56, together with HLA-B*54, compose the broad serotype B22. Nevertheless, the peptidome presented by HLA-B*54:01 shows a relatively low overlap with those of HLA-B*55:01, -B*55:02 and -B*56:01. This could be explained by the polymorphisms Glu45Gly and Ile52Val in HLA-B*54:01 compared to -B*55 and -B*56.

The analyzed peptides come both from transfected cells expressing only one HLA-B allotype and from cells expressing different HLA-A. In the last case the HLA-B molecule assignment was made based on algorithms. We cannot discard that the use of algorithms could introduce a bias in the assignment. Similarly, although the peptides were obtained by similar methodology, the large differences in the size of the peptidomes may have introduced some bias in the anchor motif, as it is expected that the peptide repertoires with a lower number of peptides are composed of the more abundant and with a higher affinity for the HLA-B molecule.

The presence of subpeptidomes among the members of the B7 supertype correlates with their ability to bind other residues than Pro2 at P2. By performing sequence alignments we were able to identify polymorphisms Glu45Thr and Tyr67Phe as important residues for the presence of subpeptidomes, except for HLA-B*54:01, that carry Gly45 and Tyr67. The crystal structures of HLA-B*07:02 show that Glu45 interacts with both Tyr67 and Asn63, a residue conserved among all the analyzed alleles. On the other hand, Thr45, present

in the alleles that bind subpeptidomes, is not able to interact with Asn63 and Phe67, as shown by the structures of HLA-B*51:01 and -B*35:01. We propose that the interactions mediated by Glu45 reorient Asn63 and, overall, change the structure of the Pocket B, making it more rigid, limiting its ability to bind residues different than Pro. Additionally, peptide bonds involving Pro are rigid and can exist in the cis-configuration due to the cycled nature of this amino acid. This characteristic could modify the interactions of the P1 residue with the Pocket A when followed by Pro, altering the HLA specificities when binding ligands with Pro at P2 compared to other residues at that position. As described elsewhere [13], the crystal structures of HLA-B*51:01 bound to a ligand with Pro2 or with Ala2 showed that, when Ala is present at P2, the P1 residue can interact with Arg62 favoring the presence of acidic and polar residues at that position, while in ligands with Pro2 this interaction is impeded, favoring the presence of non-polar residues at P1. Previously, it was described that Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) is responsible for the differential residue usage at P1 between the two subpeptidomes of HLA-B*51:01 [12]. ERAP1 trims peptides in the endoplasmic reticulum (ER) to the correct length so that they can be loaded onto the HLA molecules [42, 43]. This process occurs with different efficiency depending on the nature of the P1 residue; moreover, ERAP1 is unable to trim peptide bonds involving Pro [44]. Thus, peptides that carry an ERAP1-susceptible residue at P1 followed by an amino acid other than Pro would be degraded by the enzyme. On the other hand peptides with ERAP1-resistant P1 residues, such as Asp, a residue predominant at P1 in the Ala2 subpeptidome, will remain in the ER long enough to bind the HLA molecule and be presented on the cell surface. Since ERAP1 cannot degrade the X-Pro bond, even peptides with ERAP1-susceptible residues at P1, such as aliphatic residues, will not be degraded by the enzyme when followed by Pro and will bind HLA-B*51:01. The peptidomes presented by cells carrying ERAP1 variants with different activity [40] and by cells lacking ERAP1 [45] support this mechanism but do not fully explain the different usage at P1 between subpeptidomes, suggesting that the HLA molecules themselves exert different binding selections among the subpeptidomes. The effects of ERAP1 activity on the peptidomes presented by the different members of the B7 supertype has not yet been characterized, but its role on shaping the different subpeptidomes of these alleles could be similar to the one described for HLA-B*51:01.

The predictive affinity to HLA of the Pro2 subpeptidome was systemically higher than that of the Ala2 subpeptidome across the different members of the B7 supertype. These data are in agreement with previous data on HLA-B51 allotypes [12]. In the case of HLA-B*07:02, the theoretical affinity of the total peptidome presented a higher affinity than the Ala2-containing subpeptidome. The other 5 allotypes analyzed, which presented subpeptidomes with acid or polar residues favored in P1 did not present this lower affinity in the Ala2-containing subpeptidome. Thus, although -B*07:02 can bind peptides with Ala2, the absence of polar or acidic residues at P1 may produce a lower affinity. We cannot discard that the presence of two subpeptidomes, one of them with more peptides than the other, may result in the underestimation of the affinity of peptides belonging to the less abundant subpeptidome.

In conclusion, this work indicates that the study of the peptidomes presented by an HLA-I molecules is complex, and that a thorough analysis is required, at least among the members

of the B7 supertype, to consider differences between subpeptidomes. A detailed analysis of these subpeptidomes is necessary to understand the rules underlying HLA ligand selection and, consequently, to correctly predict which peptides have the potential to bind to and be presented by the different HLA alleles.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Funding

This work was supported by Grant RTI2018-097414-B-I00 from the Spanish Ministry of Economy and Competitiveness to I.A.

Abbreviations:

HLA	human leukocyte antigens
CTL	cytotoxic T lymphocytes
MHC	major histocompatibility complex
β2m	Beta-2 microglobulin
IEDB	Immuno Epitope Database and Analysis Resource
PRBAM	Peptide Repertoire-Based Anchor Motif
PDB	Protein Data Bank

10 References

- [1]. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC, Structure of the human class I histocompatibility antigen, HLA-A2, *Nature*, 329 (1987) 506–512. [PubMed: 3309677]
- [2]. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG, Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules, *Nature*, 351 (1991) 290–296. [PubMed: 1709722]
- [3]. Sidney J, Peters B, Frahm N, Brander C, Sette A, HLA class I supertypes: a revised and updated classification, *BMC Immunol*, 9 (2008) 1. [PubMed: 18211710]
- [4]. Hertz T, Yanover C, Identifying HLA supertypes by learning distance functions, *Bioinformatics*, 23 (2007) e148–155. [PubMed: 17237084]
- [5]. Kanguane P, Sakharkar MK, Rajaseger G, Bolisetty S, Sivasekari B, Zhao B, Ravichandran M, Shapshak P, Subbiah S, A framework to sub-type HLA supertypes, *Front Biosci*, 10 (2005) 879–886. [PubMed: 15569626]
- [6]. Lund O, Nielsen M, Kesmir C, Petersen AG, Lundegaard C, Worning P, Sylvester-Hvid C, Lamberth K, Roder G, Justesen S, Buus S, Brunak S, Definition of supertypes for HLA molecules using clustering of specificity matrices, *Immunogenetics*, 55 (2004) 797–810. [PubMed: 14963618]
- [7]. Wang M, Claesson MH, Classification of human leukocyte antigen (HLA) supertypes, *Methods Mol Biol*, 1184 (2014) 309–317. [PubMed: 25048132]

- [8]. Kikuchi A, Sakaguchi T, Miwa K, Takamiya Y, Rammensee HG, Kaneko Y, Takiguchi M, Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket, *Immunogenetics*, 43 (1996) 268–276. [PubMed: 9110930]
- [9]. Sakaguchi T, Ibe M, Miwa K, Kaneko Y, Yokota S, Tanaka K, Takiguchi M, Binding of 8-mer to 11-mer peptides carrying the anchor residues to slow assembling HLA class I molecules (HLA-B*5101), *Immunogenetics*, 45 (1997) 259–265. [PubMed: 9002446]
- [10]. Sakaguchi T, Ibe M, Miwa K, Yokota S, Tanaka K, Schonbach C, Takiguchi M, Predominant role of N-terminal residue of nonamer peptides in their binding to HLA-B* 5101 molecules, *Immunogenetics*, 46 (1997) 245–248. [PubMed: 9211752]
- [11]. Falk K, Rotzschke O, Takiguchi M, Gnau V, Stevanovic S, Jung G, Rammensee HG, Peptide motifs of HLA-B51, -B52 and -B78 molecules, and implications for Behcet's disease, *International immunology*, 7 (1995) 223–228. [PubMed: 7734418]
- [12]. Guasp P, Alvarez-Navarro C, Gomez-Molina P, Martin-Esteban A, Marcilla M, Barnea E, Admon A, Lopez de Castro JA, The Peptidome of Behcet's Disease-Associated HLA-B*51:01 Includes Two Subpeptidomes Differentially Shaped by Endoplasmic Reticulum Aminopeptidase 1, *Arthritis Rheumatol*, 68 (2016) 505–515. [PubMed: 26360328]
- [13]. Gfeller D, Guillaume P, Michaux J, Pak HS, Daniel RT, Racle J, Coukos G, Bassani-Sternberg M, The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands, *Journal of immunology*, 201 (2018) 3705–3716.
- [14]. Sarkizova S, Klaeger S, Le PM, Li LW, Oliveira G, Keshishian H, Hartigan CR, Zhang W, Braun DA, Ligon KL, Bachireddy P, Zervantonakis IK, Rosenbluth JM, Ouspenskaia T, Law T, Justesen S, Stevens J, Lane WJ, Eisenhaure T, Lan Zhang G, Clauser KR, Hacohen N, Carr SA, Wu CJ, Keskin DB, A large peptidome dataset improves HLA class I epitope prediction across most of the human population, *Nature biotechnology*, 38 (2020) 199–209.
- [15]. Saper MA, Bjorkman PJ, Wiley DC, Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution, *Journal of molecular biology*, 219 (1991) 277–319. [PubMed: 2038058]
- [16]. Carreno BM, Winter CC, Taurog JD, Hansen TH, Biddison WE, Residues in pockets B and F of HLA-B27 are critical in the presentation of an influenza A virus nucleoprotein peptide and influence the stability of peptide - MHC complexes, *International immunology*, 5 (1993) 353–360. [PubMed: 8494822]
- [17]. Mestre-Ferrer A, Scholz E, Humet-Alsius J, Alvarez I, PRBAM: a new tool to analyze the MHC class I and HLA-DR anchor motifs, *Immunology*, 156 (2019) 187–198. [PubMed: 30408168]
- [18]. Andreatta M, Nielsen M, Gapped sequence alignment using artificial neural networks: application to the MHC class I system, *Bioinformatics*, 32 (2016) 511–517. [PubMed: 26515819]
- [19]. Nielsen M, Lundegaard C, Worning P, Lauemoller SL, Lamberth K, Buus S, Brunak S, Lund O, Reliable prediction of T-cell epitopes using neural networks with novel sequence representations, *Protein Sci*, 12 (2003) 1007–1017. [PubMed: 12717023]
- [20]. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE, The Protein Data Bank, *Nucleic acids research*, 28 (2000) 235–242. [PubMed: 10592235]
- [21]. Maenaka K, Maenaka T, Tomiyama H, Takiguchi M, Stuart DI, Jones EY, Nonstandard peptide binding revealed by crystal structures of HLA-B*5101 complexed with HIV immunodominant epitopes, *Journal of immunology*, 165 (2000) 3260–3267.
- [22]. Motozono C, Kuse N, Sun X, Rizkallah PJ, Fuller A, Oka S, Cole DK, Sewell AK, Takiguchi M, Molecular basis of a dominant T cell response to an HIV reverse transcriptase 8-mer epitope presented by the protective allele HLA-B*51:01, *Journal of immunology*, 192 (2014) 3428–3434.
- [23]. Brennan RM, Petersen J, Neller MA, Miles JJ, Burrows JM, Smith C, McCluskey J, Khanna R, Rossjohn J, Burrows SR, The impact of a large and frequent deletion in the human TCR beta locus on antiviral immunity, *Journal of immunology*, 188 (2012) 2742–2748.
- [24]. Du VY, Bansal A, Carlson J, Salazar-Gonzalez JF, Salazar MG, Ladell K, Gras S, Josephs TM, Heath SL, Price DA, Rossjohn J, Hunter E, Goepfert PA, HIV-1-Specific CD8 T Cells Exhibit Limited Cross-Reactivity during Acute Infection, *Journal of immunology*, 196 (2016) 3276–3286.

- [25]. Rowntree LC, Nguyen THO, Halim H, Purcell AW, Rossjohn J, Gras S, Kotsimbos TC, Mifsud NA, Inability To Detect Cross-Reactive Memory T Cells Challenges the Frequency of Heterologous Immunity among Common Viruses, *Journal of immunology*, 200 (2018) 3993–4003.
- [26]. Chan KF, Gully BS, Gras S, Beringer DX, Kjer-Nielsen L, Cebon J, McCluskey J, Chen W, Rossjohn J, Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide, *Nature communications*, 9 (2018) 1026.
- [27]. Hwang MS, Miller MS, Thirawatananond P, Douglass J, Wright KM, Hsiue EH, Mog BJ, Aytenfisu TY, Murphy MB, Aitana Azurmendi P, Skora AD, Pearlman AH, Paul S, DiNapoli SR, Konig MF, Bettgowda C, Pardoll DM, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S, Gabelli SB, Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens, *Nature communications*, 12 (2021) 5271.
- [28]. Lineburg KE, Grant EJ, Swaminathan S, Chatzileontiadou DSM, Szeto C, Sloane H, Panikkar A, Raju J, Crooks P, Rehan S, Nguyen AT, Lekieffre L, Neller MA, Tong ZWM, Jayasinghe D, Chew KY, Lobos CA, Halim H, Burrows JM, Riboldi-Tunncliffe A, Chen W, D'Orsogna L, Khanna R, Short KR, Smith C, Gras S, CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses, *Immunity*, 54 (2021) 1055–1065 e1055. [PubMed: 33945786]
- [29]. Smith KJ, Reid SW, Stuart DI, McMichael AJ, Jones EY, Bell JI, An altered position of the alpha 2 helix of MHC class I is revealed by the crystal structure of HLA-B*3501, *Immunity*, 4 (1996) 203–213. [PubMed: 8624811]
- [30]. Menssen R, Orth P, Ziegler A, Saenger W, Decamer-like conformation of a nona-peptide bound to HLA-B*3501 due to non-standard positioning of the C terminus, *Journal of molecular biology*, 285 (1999) 645–653. [PubMed: 9878435]
- [31]. Probst-Kepper M, Hecht HJ, Herrmann H, Janke V, Ocklenburg F, Klempnauer J, van den Eynde BJ, Weiss S, Conformational restraints and flexibility of 14-meric peptides in complex with HLA-B*3501, *Journal of immunology*, 173 (2004) 5610–5616.
- [32]. Miles JJ, Elhassen D, Borg NA, Silins SL, Tynan FE, Burrows JM, Purcell AW, Kjer-Nielsen L, Rossjohn J, Burrows SR, McCluskey J, CTL recognition of a bulged viral peptide involves biased TCR selection, *Journal of immunology*, 175 (2005) 3826–3834.
- [33]. Tynan FE, Elhassen D, Purcell AW, Burrows JM, Borg NA, Miles JJ, Williamson NA, Green KJ, Tellam J, Kjer-Nielsen L, McCluskey J, Rossjohn J, Burrows SR, The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation, *The Journal of experimental medicine*, 202 (2005) 1249–1260. [PubMed: 16275762]
- [34]. Hourigan CS, Harkiolaki M, Peterson NA, Bell JI, Jones EY, O'Callaghan CA, The structure of the human allo-ligand HLA-B*3501 in complex with a cytochrome p450 peptide: steric hindrance influences TCR allo-recognition, *European journal of immunology*, 36 (2006) 3288–3293. [PubMed: 17109469]
- [35]. Miles JJ, Borg NA, Brennan RM, Tynan FE, Kjer-Nielsen L, Silins SL, Bell MJ, Burrows JM, McCluskey J, Rossjohn J, Burrows SR, TCR alpha genes direct MHC restriction in the potent human T cell response to a class I-bound viral epitope, *Journal of immunology*, 177 (2006) 6804–6814.
- [36]. Archbold JK, Macdonald WA, Miles JJ, Brennan RM, Kjer-Nielsen L, McCluskey J, Burrows SR, Rossjohn J, Alloreactivity between disparate cognate and allogeneic pMHC-I complexes is the result of highly focused, peptide-dependent structural mimicry, *The Journal of biological chemistry*, 281 (2006) 34324–34332. [PubMed: 16963442]
- [37]. Gras S, Kedzierski L, Valkenburg SA, Laurie K, Liu YC, Denholm JT, Richards MJ, Rimmelzwaan GF, Kelso A, Doherty PC, Turner SJ, Rossjohn J, Kedzierska K, Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses, *Proceedings of the National Academy of Sciences of the United States of America*, 107 (2010) 12599–12604. [PubMed: 20616031]
- [38]. Liu YC, Chen Z, Neller MA, Miles JJ, Purcell AW, McCluskey J, Burrows SR, Rossjohn J, Gras S, A molecular basis for the interplay between T cells, viral mutants, and human leukocyte antigen micropolymorphism, *The Journal of biological chemistry*, 289 (2014) 16688–16698. [PubMed: 24759101]

- [39]. Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, Wheeler DK, Sette A, Peters B, The Immune Epitope Database (IEDB): 2018 update, *Nucleic acids research*, 47 (2019) D339–D343. [PubMed: 30357391]
- [40]. Guasp P, Barnea E, Gonzalez-Escribano MF, Jimenez-Reinoso A, Regueiro JR, Admon A, Lopez de Castro JA, The Behcet's disease-associated variant of the aminopeptidase ERAP1 shapes a low-affinity HLA-B*51 peptidome by differential subpeptidome processing, *The Journal of biological chemistry*, 292 (2017) 9680–9689. [PubMed: 28446606]
- [41]. Marino SR, Lin S, Maiers M, Haagenson M, Spellman S, Klein JP, Binkowski TA, Lee SJ, van Besien K, Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation, *Bone marrow transplantation*, 47 (2012) 217–226. [PubMed: 21441965]
- [42]. Saric T, Chang SC, Hattori A, York IA, Markant S, Rock KL, Tsujimoto M, Goldberg AL, An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides, *Nat Immunol*, 3 (2002) 1169–1176. [PubMed: 12436109]
- [43]. Serwold T, Gonzalez F, Kim J, Jacob R, Shastri N, ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum, *Nature*, 419 (2002) 480–483. [PubMed: 12368856]
- [44]. Hearn A, York IA, Rock KL, The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum, *Journal of immunology*, 183 (2009) 5526–5536.
- [45]. Guasp P, Lorente E, Martin-Esteban A, Barnea E, Romania P, Fruci D, Kuiper JW, Admon A, Lopez de Castro JA, Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet's Disease-associated HLA-B*51 Peptidome, *Mol Cell Proteomics*, 18 (2019) 1491–1510. [PubMed: 31092671]

Highlights:

- - Molecules of the HLA B7 supertype differ in the prevalence of Ala2 in addition of the canonical Pro2.
- - We found three different patterns in the B7 supertype molecules: i) non-presence of subpeptidomes, ii) subpeptidomes with Pro2 and Ala2 with acid residues favored in P1, and iii) subpeptidomes with Pro2 and Ala2 with polar residues favored in P1.
- - B*54:01 presents a subpeptidome where Ala2 peptides favor Glu1 over Asp1 (favored in B*51:01 and B*51:08).
- - Polymorphisms in position 45 and 67 of the α -chain are important for the presence of subpeptidomes in the B7 supertype allotypes.

AA Pos.	10	20	30	40	50	60	70	80	90	100
B*07:02	GSHSMRYFYT	SVSRPGRGEP	RFISVGIVDD	TQFVRFDSDA	ASPREEPRAP	WIEQEGPEYW	DRNTQIYKAQ	AQTDRESLRN	LRGYYNQSEA	GSHTLQSMYG
B*07:04	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
B*42:01	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
B*55:01	-----	AM-----	-----A-----	-----	-----	-----	-----	-----	-----	-----W-T-----
B*55:02	-----	AM-----	-----A-----	-----	-----	-----	-----	-----	-----	-----W-T-----
B*56:01	-----	AM-----	-----A-----	-----	-----	-----	-----	-----	-----	-----W-T-----
B*35:01	-----	AM-----	-----A-----	-----	-----T-----	-----	-----F-TN	T--Y-----	-----	-----II-R-----
B*35:03	-----	AM-----	-----A-----	-----	-----T-----	-----	-----F-TN	T--Y-----	-----	-----II-R-----
B*35:07	-----	AM--V-----	-----A-----	-----	-----T-----	-----	-----F-TN	T--Y-----	-----	-----II-R-----
B*53:01	-----	AM-----	-----A-----	-----	-----T-----	-----	-----F-TN	T--Y--N--I	ALR-----	-----II-R-----
B*51:01	-----	AM-----	-----A-----	-----	-----T-----	-----	-----F-TN	T--Y--N--I	ALR-----	-----W-T-----
B*51:08	-----	AM-----	-----A-----	-----	-----T-----	-----	-----F-TN	T--Y--N--I	ALR-----	-----W-T-----
B*54:01	-----	AM-----	-----A-----	-----	-----G-----	-V-----	-----	-----	-----	-----W-T-----

AA Pos.	110	120	130	140	150	160	170	180	190	200
B*07:02	CDVGPDGRLL	RGHDQYAYDG	KDYIALNEDL	RSWTAADTAA	QITQRKWEAA	REAEQRRAYL	EGECVFWLRR	YLENGKDKLE	RADPPKTHVT	HHPIDHEAT
B*07:04	-----	-----	-----	-----	-----	-----D-----	-----	-----	-----	-----
B*42:01	-----	--N-----	-----	-----	-----	-V--D-----	-T-----	-----T-----	-----	-----
B*55:01	--L-----	--N-L-----	-----S-----	-----	-----	-----L-----	-T-----	-----ET-Q-----	-----	-----
B*55:02	--L-----	--N-L-----	-----S-----	-----	-----	-V--L-----	-T-----	-----ET-Q-----	-----	-----
B*56:01	--L-----	--N-L-----	-----S-----	-----	-----	-V--L-----	-L-----	-----ET-Q-----	-----	-----
B*35:01	--L-----	-----S-----	-----S-----	-----	-----	-V--L-----	-L-----	-----ET-Q-----	-----	-----V-----
B*35:03	--L-----	-----F-----	-----S-----	-----	-----	-V--L-----	-L-----	-----ET-Q-----	-----	-----V-----
B*35:07	--L-----	-----S-----	-----S-----	-----	-----	-V--L-----	-L-----	-----ET-Q-----	-----	-----V-----
B*53:01	--L-----	-----S-----	-----S-----	-----	-----	-V--L-----	-L-----	-----ET-Q-----	-----	-----V-----
B*51:01	-----	--N-----	-----S-----	-----	-----	-----L-----	-L-----	H-----ET-Q-----	-----	-----V-----
B*51:08	-----	--N-----	-----S-----	-----	-----	-V--D-----	-L-----	H-----ET-Q-----	-----	-----V-----
B*54:01	--L-----	--N-L-----	-----S-----	-----	-----	-V--L-----	-T-----	-----ET-Q-----	-----	-----

Figure 1.

Sequence alignment of the 13 B7 supertype allotypes. Primary sequences of the HLA-I molecules analyzed in this work were aligned and variable residues with regard to HLA-B*07:02 are indicated.




Figure 2. Differential residue usage at the N-terminal position (P1) between HLA-B*51:01, -B*51:08 and -B*54:01 ligands with Pro at position 2 (P2) or Ala at position 2 (A2).

The single-letter code for amino acids is used. Left panels, Position 1 residue frequencies among peptides with Pro2 (P2, black) or Ala2 (A2, white). Residues are sorted according to their chemical features. Statistically significant differences, as determined by the chi-square test with Bonferroni correction were indicated as * < 0.05 and ** < 0.01. Right panels, frequency of residues at P1 grouped by their chemical nature.




Figure 3. Differential residue usage at the N-terminal position (P1) between HLA-B*35:01, -B*35:03, -B*35:07 and -B*53:01 ligands with Pro at position 2 (P2) or Ala at position 2 (A2). The single-letter code for amino acids is used. Left panels, Position 1 residue frequencies among peptides with Pro2 (P2, black) or Ala2 (A2, white). Residues are sorted according to their chemical features. Statistically significant differences, as determined by the chi-square test with Bonferroni correction were indicated as * < 0.05 and ** < 0.01 . Right panels, frequency of residues at P1 grouped by their chemical nature.




Figure 4. Differential residue usage at the N-terminal position (P1) between HLA-B*07:02, -B*07:04, -B*42:01, -B*55:01, -B*55:02 and -B*56:01 ligands with Pro at position 2 (P2) or Ala at position 2 (A2).

The single-letter code for amino acids is used. Left panels, Position 1 residue frequencies among peptides with Pro2 (P2, black) or Ala2 (A2, white). Residues are sorted according to their chemical features. Statistically significant differences, as determined by the chi-square test with Bonferroni correction were indicated as * < 0.05 and ** < 0.01. Right panels, frequency of residues at P1 grouped by their chemical nature.




Figure 5: A-C. Representation of residues 45, 63 and 67 in HLA-B*07:02, -B*35:01 and -B*51:01.
 HLA in HLA-B*07:02 (A), -B*35:01 (B) and -B*51:01 (C). D. Superposition of HLA-B*07:02 (red), -B*35:01 (blue) and B*51:01 (green). Residues 46, 63 and 67 are represented as sticks. Polar contacts are represented as dotted yellow lines. PDB entries: 1E27, 1A1N and 6UJ7.




Figure 6. Theoretical binding affinity to HLA of the subpeptidomes of the members of the B7 supertype.

The %Rank of the peptides belonging to the whole petidome (total), the Pro2 subpeptdiome (P2) and the Ala2 subpeptdiome (A2) to their respective HLA molecule is indicated.

Symbols represent individual peptides; horizontal lines represent the median. * = $0.01 < P < 0.1$; ** = $0.001 < P < 0.01$; *** = $0.001 < P < 0.01$; **** = $P < 0.0001$ by Mann-Whitney U test.

Table 1.

General features of the B7 supertype peptidomes.

HLA-B*	Total	Peptides by number of residues (%)						AAs average
		8	9	10	11	12	13	
07:02	12033	7.83	49.49	21.94	12.29	5.68	2.78	9.67
07:04	1480	5.74	61.22	20.00	10.34	1.89	0.81	9.44
35:01	1954	5.27	57.37	17.14	11.67	5.53	3.02	9.64
35:03	1527	4.78	76.36	10.35	6.09	1.83	0.59	9.26
35:07	1933	3.31	68.39	14.49	9.67	2.69	1.45	9.44
42:01	3428	5.86	59.42	17.53	12.95	2.92	1.31	9.52
51:01	5157	27.38	55.85	8.45	4.07	2.39	1.86	9.04
51:08	624	13.62	77.88	4.17	3.04	1.28	0.00	9.00
53:01	2204	4.54	63.43	17.56	9.62	3.58	1.27	9.48
54:01	1441	11.24	52.26	16.52	12.28	4.44	3.26	9.56
55:01	1548	11.30	55.81	19.77	9.04	2.39	1.68	9.40
55:02	1549	3.42	54.36	22.66	13.43	4.13	2.00	9.66
56:01	2113	4.92	51.49	24.33	13.54	3.74	1.99	9.66

Table 2.

Immunopeptidome overlap.

Peptide Number		12033	1480	1954	1527	1933	3428	5157	624	2204	1441	1548	1549	2113
	HLA allotype													
12033	B*07:02		822	228	314	199	1693	203	33	181	82	286	230	271
1480	B*07:04	55.5 \ 6.8		25	59	41	878	32	9	36	19	120	80	85
1954	B*35:01	11.7 \ 1.9	1.3 \ 1.7		246	865	115	153	3	452	68	9	22	25
1527	B*35:03	20.6 \ 2.6	3.9 \ 4.0	16.1 \ 12.6		371	237	93	12	322	45	34	39	55
1933	B*35:07	10.3 \ 1.7	2.1 \ 2.8	44.7 \ 44.3	19.2 \ 24.3		168	60	3	613	28	21	31	42
3428	B*42:01	49.4 \ 14.1	25.6 \ 59.3	3.4 \ 5.9	6.9 \ 15.5	4.9 \ 8.7		129	49	149	66	238	191	209
5157	B*51:01	3.9 \ 1.7	0.6 \ 2.2	3.0 \ 7.8	1.8 \ 6.1	1.2 \ 3.1	2.5 \ 3.8		337	178	215	100	99	130
624	B*51:08	5.3 \ 0.3	1.4 \ 0.6	0.5 \ 0.2	1.9 \ 0.8	0.5 \ 0.2	7.9 \ 1.4	54.0 \ 6.5		34	30	23	25	25
2204	B*53:01	8.2 \ 1.5	1.6 \ 2.4	20.5 \ 23.1	14.6 \ 21.1	27.8 \ 31.7	6.8 \ 4.3	8.1 \ 3.5	1.5 \ 5.4		37	32	36	41
1441	B*54:01	5.7 \ 0.7	1.3 \ 1.3	4.7 \ 3.5	3.1 \ 2.9	1.9 \ 1.4	4.6 \ 1.9	14.9 \ 4.2	2.1 \ 4.8	2.6 \ 1.7		226	329	425
1548	B*55:01	18.5 \ 2.4	7.8 \ 8.1	0.6 \ 0.5	2.2 \ 2.2	1.4 \ 1.1	15.4 \ 6.9	6.5 \ 1.9	1.5 \ 3.7	2.1 \ 1.5	14.6 \ 15.7		710	777
1549	B*55:02	14.8 \ 1.9	5.2 \ 5.4	1.4 \ 1.1	2.5 \ 2.6	2.0 \ 1.6	12.3 \ 5.6	6.4 \ 1.9	1.6 \ 4.0	2.3 \ 1.6	21.2 \ 22.8	45.8 \ 45.9		1207
2113	B*56:01	12.8 \ 2.3	4.0 \ 5.7	1.2 \ 1.3	2.6 \ 3.6	2.0 \ 2.2	9.9 \ 6.1	6.2 \ 2.5	1.2 \ 4.0	1.9 \ 1.9	20.1 \ 29.5	36.8 \ 50.2	57.1 \ 77.9	

Note: Above the diagonal, absolute numbers of shared peptides are indicated. Under the diagonal, percentage that the shared peptide represents on the total number of peptides in the peptidomes (the number before backslash correspond to the allotype indicated in the left, and the number after backslash corresponds to the allotype indicated above).

Note: Light grey shows that shared peptides represent more than 20% of the total peptidome of at least one of the pair. Dark shows that shared peptides represent more than 20% of the total peptidome of at least one of the pair.

Table 3.

Amino acid presence at the peptide position 2 among the peptidomes of the B7 supertype molecules.

	Total	P2	A2	Others
HLA-B*07:02	12033	9956 (82.7%)	338 (2.8%)	1739 (14.5%)
HLA-B*07:04	1480	1233 (83.3%)	58 (3.9%)	189 (12.8%)
HLA-B*35:01	1954	1322 (67.7%)	297 (15.2%)	335 (17.1%)
HLA-B*35:03	1527	1251 (81.9%)	177 (11.6%)	99 (6.5%)
HLA-B*35:07	1933	1373 (71.0%)	399 (20.6%)	161 (8.3%)
HLA-B*42:01	3428	2987 (87.1%)	100 (2.9%)	341 (9.9%)
HLA-B*51:01	5157	2566 (49.8%)	1552 (30.1%)	1039 (20.1%)
HLA-B*51:08	624	285 (45.7%)	339 (54.3%)	0 (0.0%)
HLA-B*53:01	2204	1600 (72.6%)	436 (19.8%)	168 (7.6%)
HLA-B*54:01	1441	1038 (72.0%)	145 (10.1%)	258 (17.9%)
HLA-B*55:01	1548	1378 (89.0%)	42 (2.7%)	128 (8.3%)
HLA-B*55:02	1549	1407 (90.8%)	40 (2.6%)	102 (6.6%)
HLA-B*56:01	2113	1873 (88.6%)	54 (2.6%)	186 (8.8%)

Table 4.

Residues at positions 45, 67 and 116 in the HLA-I molecules analyzed.

HLA MOLECULE	POSITION			MAIN PEPTIDE RESIDUE AT PΩ
	45	67	116	
B*07:02	E	Y	Y	Leu or Met
B*07:04	-	-	-	Leu or Met
B*42:01	-	-	-	Leu or Met
B*55:01	-	-	L	Ala or Val
B*55:02	-	-	L	Ala or Val
B*56:01	-	-	L	Ala or Val
B*35:01	T	F	S	Aromatic
B*35:03	T	F	F	Leu or Met
B*35:07	T	F	S	Aromatic
B*53:01	T	F	S	Aromatic
B*51:01	T	F	-	Leu or Val
B*51:08	T	F	-	Leu or Val
B*54:01	G	-	L	Ala or Val